O. Ghatnekar, F. Hjalte, and M. Taylor, “Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application”, AO, vol. 49, no. 6, pp. 851–858, Aug. 2010.